Vyvanse added to the Essential Formulary with Prior Authorization and Step Therapy

Effective June 1, 2022, Vyvanse capsules and chewable tablets will be added to the Essential Formulary as tier 4 medications.  Vyvanse will require prior authorization with step therapy before a member will receive approval for the drug. .  The existing quantity limit of 1 capsule/tablet per day will remain in place.   

No additional authorization is needed if a prior authorization was approved for a member in 2022, while Vyvanse required a formulary exception. 

The new coverage policy can be found here.